Final Project

Mass Pharma (Private) Limited1. Introduction

Mass Pharma (Pvt.) Limited is also situated in the same historical city of Lahore and very

proudly claims to be one of the most professionally designed pharmaceutical industry of

Pakistan. Mass Pharma started its operation in 1998. The company has emerged as one of the

fastest growing companies among the Pharma industry of Pakistan by manufacturing quality

products of international standards which have been acknowledged by the Health Care

Professionals all over the country and can be very rightly said that Mass Pharma is among one of

the leading pharmaceutical quality conscious companies.

We have the slogan to work for Masses Health Care. The Company is involved in the

manufacturing of almost all segments of products having its six independent manufacturing

sections which are controlled with centrally air-handling system.

Mass Pharma is a component of Khawaja Group of Companies which is dealing in

Pharmaceutical Business since last more than 30 years with the aim to serve the ailing humanity,

having annual turnover of more than 0.5 billion, which clearly shows the national wide faith of

the medical professional and it is mainly based on offering of the international standard

pharmaceutical products at affordable price.

1

Mass Pharma (Private) Limited2. President's Vision

I feel pleasure in stating that my dream is fulfilled, by adding a pharmaceutical manufacturing

unit in the chain of Khawaja Group of Companies. I was working on this project since long. My

dream became true with the moral and financial support of all the directors on board of Mass

Pharma.

I pray my cordial thanks to the chairman specially and all the directors generally for their

positive role they have played for the completion of building, selection of machinery for

production as well as procurement of quality control equipment till the production of quality

products in an environment of international standards within the plant and around it. And also for

those who worked in the field of marketing in such a way that Mass Pharma is known throughout

the country as one of the leading pharmaceutical company.

My message to all those who believe in execution of dream are:

“Dreams are very important to see but only for those who have the courage to realize their

dreams,”

Similarly a successful person and mentor, who believe in hard working, can rightly say that…….

The height the successful men reached and kept

was not attained by sudden flight

they while their companion slept

were tolling upward in the nigh

2

Mass Pharma (Private) Limited3. Profile

For the health care of masses, Mass Pharma stands committed for production of high quality

products at an affordable price.

Mass Pharma has embarked on a journey of success; the destination is very bright and intends to

be a part of that beacon, showing rays of hope, offering solace to ailing humanity in Pakistan.

Manufacturing facilities at its unit have been kept environmental friendly, which is conductive

for an impeccable storage and manufacturing process starting right from receipt of raw material

up to the delivery of products in finished form.

Mass Pharma has collaboration with a UK based multinational pharmaceutical company for

manufacturing of their dermatological and cardiovascular range. Mass Pharma has the honor to

manufacture and market cardiac products of multinational company.

For Masses’ Health Care, Mass Pharma manufactures ANTIBIOTICS, NSAIDs,

ANTIULCERANTS, HAEMOSTATICS, IMMUNOSUPPRESSANT and Third Generation

CEPHALOSPORIN Parental / Oral Formulations.

3

Mass Pharma (Private) Limited4. Marketing & Sales:

Mass Pharma marketing and sales department has a team of 150 well groomed and experienced

sales professionals. Objective is to provide latest medical / product information to the medical

profession through ethical promotional network.

The department is headed by Executive Director Sales & Marketing, a highly respected

professional, having experience of more than 35 years of multinational and national companies.

Marketing department also consist of personnel development unit headed by a qualified medical

graduate having cardiology as specialty to his credit. Objective of this department is to provide

medical / product knowledge to young entrants and to provide latest medical update to the

medical profession.

Product management unit is another area of esteem of marketing and sales department in which

highly professional people are involved for continuous search for new molecules and to improve

delivery options of the existing molecules.

4

Mass Pharma (Private) Limited5. Manufacturing Unit

The manufacturing facility is situated at 17-Km, Ferozepur Road, Lahore, Pakistan. This facility

having a layout according to the international standard is centrally air conditioned and is

equipped with latest machinery.

The factory has six separate sections for the manufacturing of following formulations:

Tablets

Capsules

Dry Powder Suspensions

Liquid Injectables

Dry Powder Injectables

Cream & Ointments

To control temperature, humidity and to avoid cross contamination during manufacturing

process, all sections have independent air handling system.

Production capacity has been designed to meet the marketing demand of foreign and local

collaborations along with its own marketing requirements for the next two decades.

5

Mass Pharma (Private) Limited

6. Organization Structure

The Board of Directors is comprised of a group of highly dedicated professionals who have been

actively engaged in the pharmaceutical business for more than 2.5 decades. The founder and

Chief Executive of Mass Pharma has 25 year’s experience at his credit for import, distribution

and marketing of some of the renowned multinational and national pharmaceutical products

under the umbrella of Mass Pharma sister concern, K. S. Mass, Pharmaceutical Distributors. The

Chief Executive of Mass Pharma has been incorporating his rich experience for the growth and

development of the Company right from its initial phase. As a result of these efforts of

management, Mass Pharma is right on track to achieve its ultimate objective, “to be among the

top ten Pharmaceutical Companies of Pakistan within next five years. INSHA-ALLAH”

6

Chairman

CEO

DirectorQuality Contorl

DirectorMarketing

DirectortorSales

DirectorManufacture

President

Vice President


Handle with care

7


7. Glip: (Product which we launch)

Glip (Glipmepiride) is approved for once daily use as monotherapy or in combination with

insulin. Glimepiride achieves blood glucose lowering with the lowest dose of any sulphonylurea

compound. A single daily dose of 1mg has been shown to be effective and the recommended

maximal daily dose is 8mg. it has a long duration of action with a half life of 5 hour, allowing

once daily dosing & thereby improving compliance.

Glip 1, 2 & 4 mg

(Glimipride)

Referred sometimes as a third generation Sulphonyl Urea

Mode of Action

Glip work at the cellular level to stimulate the release of insulin from the pancreas. Glip effects on beta cells of pancreas Glip effect at target tissues outside the pancreas Glip seems to stimulate insulin production primarily after meals, when glucose levels are

highest, but the drug provide glucose control throughout the day Older SU’s may cause hyperinsulinemia Hyperinsulinemia can promote weight gain and increase risk of hypoglycemia Binding to K-ATP channels, causing Opening of Ca channel which Simulates insulin release

Pharmacokinetics

The Pharmacokinetics effect of Glip do not vary with age or gender Absorption Glip is completely absorbed after oral administration

8

Mass Pharma (Private) Limited 100% absorbed from GIT after oral administration and reaches maximum concentration

after 2-3 hrs. Glip remains in blood circulation and extra cellular fluid Highly protein binding 99.5% The binding is weak, therefore it easily moves from plasma protein to the cell surface

receptor Metabolites of Glip have little or no biological activity Glip has other effects on the body that affect diabetes therapy

Indications

Glip decrease blood glucose by: Increasing Glycogen synthesis (by increasing activity of glycogen synthase) Increase Glut 4 transporters at cell surfaces No effect on plasma lipid levels NIDDM Where every blood sugar level cannot be controlled adequately by: Diet Physical Exercise Weight Reduction

Glip 1, 2 & 4 mg

(Glimepride)

Opening Doctor, in the treatment of type II Diabetes Mellitus your

main concern is to control fasting plasma glucose level and

random Plasma Glucose level Moreover according to UKPDS

HbA1c level are very important in the tight control of diabetes

Showing the cover page Doctor! You will agree that mostly the diabetic patient is

deprived of life but!

We have a solution and that is Glip tab contain Glimipride

available in 1, 2 & 4 mg that keeps the color of life.

Show page after the cover page Sir,

Glip (Glimepride) is a well established third generation

sulfonylurea for the management of type II diabetes Mellitus.

9

Mass Pharma (Private) LimitedGlip Provide

24 Hrs effective glycemic control

No significant effect on weight gain

Low incidence of hypoglycemia

Prevents Diabetic Complications

Doctor Glip provide effective glycemic control (Demonstrate

the Graph that Glip regulate the HbA1c level at the normal

figure of 7 that is the requirement of FDA)

Show the second page Sir,

Glip has no significant effects on weight gain (Discuss the

graph with doctor)

Moreover, Low incidence of Hypoglycemia with Glip

Glimepride provide 24 hrs glycemic control without inducing

hypoglycemia

(Discuss the graph with doctor)

Similarly Glip prevents diabetic complications

According to UKPDS 1% reduction HbA1c prevents

complications up to 33%

(Discuss the graph with doctor)

And Glip provide 2.4% reduction in HbA1c level

Show the back page So Doctor, we can conclude that:

Glip

Controls glucose 24hrs, with a smaller dose Better patient compliance once daily dosage FDA approved for use in combination with insulin and

metformin Alu Alu packaging

Take Commitment offer Literature/Sample and close the

call

Doctor looking at the beautiful profile and keeping in view

Glitter offers tight glycemic control with reduction in

complications. How do you feel to prescribe Glip to the

10

Mass Pharma (Private) Limitedoncoming patient with type II diabetes?

Foundation for next call Doctor, in my next visit I’ll share your clinical experience

regarding Glip.

8. SWOT ANALYSIS

8.1Strengths

The Quality Advantage

Glip decrease blood glucose by: Increasing Glycogen synthesis (by increasing activity of glycogen synthase) Increase Glut 4 transporters at cell surfaces No effect on plasma lipid levels NIDDM Where every blood sugar level cannot be controlled adequately by: Diet Physical Exercise Weight Reduction

A Buying Choice:

Mass Pharma has a sales network of almost all cities of the Pakistan cities, with a

workforce of over 4500 trained sales personnel to guide our customers in finding the

right tab. Our high sales and customer care standards led us to achieve higher in

cardiology.

Quality Control

At Mass Pharma, Quality Control not only means to carry out few analytical procedures

in the laboratory at the end of the production, but is a series of procedures which keeps a

microscopic eye on each step of transformation from raw material to finished products,

thus ensuring manufacturing of right quality products. Quality control division has

independent sections for chemical testing, instruments room and microbiological testing

laboratory.

8.2 Weaknesses11

Mass Pharma (Private) LimitedCommodity Price Risks

Mass Pharma commodity price risks to higher costs due to changes in prices of inputs

such as Salt, Powder, Plastic and etc, which go into the production of Pharmacy Product.

In order to mitigate these risks, the company continues to attempts to enter into long

term contracts based on its projections of prices. In a volatile commodity market, where

your company gives top priority to ensuring smooth availability of inputs, long term

contracts are helpful. They also help minimize the impact of growing input prices.

Conversely, long term contracts dilute the benefits, if any of a decline in input prices.

Exchange Rate Risk

The company is exposed to the risks associated with fluctuations in foreign exchange

rates mainly of import of components & raw materials and export of vehicles. The

company has a well structured exchange risk management policy. The company

manages the exchange risk by using appropriate hedge instruments depending on the

prevailing market conditions and the view on the currency

8.3 Opportunities:

Leading Growth

Mass Pharma is one of the few National Pharmaceutical companies who have been awarded with

European Certification. It is another milestone in the history of Mass Pharma that a European

based Pharmaceutical Company has joined hands with Mass Pharma for the production of its

world renowned products and that too after confirming its International standard of production

facility and quality control.

8.4 Threats

Risk Factors

In the course of its business, Mass Pharma is exposed to a variety of market and other risks

including the effects of demand dynamics, commodity prices, currency exchange rates, interest

rates, as well as risk associated with financial issues, hazard events and specific assets risk.

Whenever possible, we use the instrument of insurance to mitigate the risk.

Business Risks

12

Mass Pharma (Private) LimitedThe Pharmacy industry is very capital intensive. Such investments require a certain scale of

operation to generate viable returns. These scales depend on demand. Although 2007-08 was

year of continued deprecation for the world economy whether this growth effect.

Threats from Competitors

Getz Limited

For the fiscal year ended December 2007, Getryl generated revenues of $193,517 million, an

increase of 4.3% from the previous year. The company reported a net income of $2,805 million

for fiscal 2005, down 26.6% from the previous year.

CCL Limited

In the 2007 fiscal year, CCL Motors generated revenues of $3,542.2 million (INR154, 935.2

million). The company made a net profit of $185 million (INR8, 103.4 million) in the 2006 fiscal

year.

9. Marketing Strategy

9.1 Objectives

Quantitative:

Each SPO/PS has to achieve 100% value wise target of Glip in Quarter IV

2008-09

Qualitative:

Establish Glip as first line treatment in type 2 Diabetes i.e. newly diagnosed/swith

over of type 2 patient

Retain Glip prescribers

Further establish efficacy of Glip, which is well proven backed by strong image of

Mass Pharma

Increase patient awareness on Diabetes management

An important objective will be to establish a well-regarded brand name linked to a meaningful

positioning. We will have to invest heavily in marketing to create a memorable and distinctive

13

Mass Pharma (Private) Limitedbrand image projecting innovation, quality and value. We also must measure awareness and

response so we can adjust our marketing efforts if necessary.

9.2 Target Markets

Product Segmentation & target Audience

Core Products: (Glips, Blaze, Lipivastin)

Cardiologists

Diabetologists

Medical Specialists

Nephrologists

Neurophyscians

Chest Physicians

G.I. Physicians

A-Class Family Physicians

9.3 Positioning

Type 2 Diabetes Mellitus

9.4 Strategies

Product

Glip (Glipmepiride) is approved for once daily use as monotherapy or in combination with

insulin. Glimepiride achieves blood glucose lowering with the lowest dose of any sulphonylurea

compound. A single daily dose of 1mg has been shown to be effective and the recommended

maximal daily dose is 8mg. it has a long duration of action with a half life of 5 hour, allowing

once daily dosing & thereby improving compliance.

Price

Glip 1 mg 30’s 76.50 90 32 mg 30’s 127.50 150 54 mg 20’s 170 200 10

14


9.5 Marketing Communications

By integrating all messages in all media we will reinforce the brand name & main points of

product differentiation. Research about media consumption, pattern will help our advertising

agency to choose appropriate media and timing to reach prospects before & during the product

introduction. Thereafter, advertising will appeared on a pulsing basis to maintain brand

awareness and communicate various differentiation messages. The agency wills also co-ordinate

public relation efforts to build Mass Pharma brand & support the differentiation message. To

attract market attention & encourage purchasing, we will offer a limited time, registration &

insurance.

9.6 Marketing Mix

Product

Features:

The Pharmacokinetics effect of Glip do not vary with age or gender Absorption Glip is completely absorbed after oral administration

15

Mass Pharma (Private) Limited 100% absorbed from GIT after oral administration and reaches maximum concentration

after 2-3 hrs. Glip remains in blood circulation and extra cellular fluid Highly protein binding 99.5% The binding is weak, therefore it easily moves from plasma protein to the cell surface

receptor Metabolites of Glip have little or no biological activity Glip has other effects on the body that affect diabetes therap

Price

Glip 1 mg 30’s 76.50 90 32 mg 30’s 127.50 150 54 mg 20’s 170 200 10

PromotionPromotional Tactics:

Proper detail to the existing doctor and new doctors Quality advantage should be forcefully communicated to enhance the image of your

product and company. Focus the doctor prescribing Getryl, Evopride and Orinase, use the rule of 50/50 to

convert such doctor At least one sugar camp in each SPO/PSABE territory per month should be conducted

strictly. 2 RTD’s should also be conducted in the area of each manager. Wall mountings of diet chart for diabetic patients in the doctor chamber, 25 for each

manager

16


Place

To meet the challenges of product placement, Mass Pharma has a sister concern under the title of

K. S. Mass, Pharmaceutical Distributors, whose prime function is to appoint local distributors at

district level of the country for distribution of Mass Pharma products.

Currently the following cities are covered under the distribution network.

Abbottabad Bannu Bahawalpur Bahawalnagar D.I.Khan D.G.Khan Faisalabad Gujranwala Gujrat Hyderabad Jacobabad Jhang Jehlum Kohat Kasur Lahore Larkana

Multan Mirpur Khas Mianwali Mingora Mardan Nawabshah Okara Peshawar Rawalpindi R. Y. Khan Sheikhupura Sahiwal Sargodha Sukkur Sialkot Toba Tek Singh Timergara Vehari

17


10. PRODUCT LIFE CYCLE

10.1 IntroductionAs a new product much time will be spent by the organization to

create awareness of it presence amongst its target market. Profits are

negative or low because of this reason.

10.2 Growth

If consumer clearly feels that this product will benefit them in some ways and they accept it, the

organization will see a period of rapid sales growth. Mass stands on Growth Stage. As the sales

18

Mass Pharma (Private) Limitedof Glip is high as compare to CCL Orinase then the consumer will buy Glip by providing them

with great benefits in future and they will accept it.

10.3 Maturity

Rapid sales growth cannot last forever. Sales slow down as the product sales reach peak as it has

been accepted by most buyers.

10.4 Decline

Sales and profits start to decline, the organisation may try to change their pricing strategy to

stimulate growth, and however the product will either have to be re-modified, or replaced within

the market.

19


11. Rules of Fifty Fifty

50% of the target will be achieved by our following tools

Samples Literatures Gifts Field operative standards Contacts due to pervious Mass investments Technical skills Experience Thorough working

Rest of 50% will be achieved by the Activities & Investment of the Company.

20


12. Field Operative Standards

Of DAFFODIL Group for SPO’s and PS’s

Core products (Headquarter)

DRS. Class No. of DRS. Visits/Month Total VisitsA-4(Headquarter)

10 4 40

A-3(Headquarter)

20 3 60

100

General Products (Headquarter)

DRS. Class No. of DRS. Visits/Month Total VisitsA-4(Headquarter)

10 4 40

A-3(Headquarter)

20 3 60

100

Total NO of HQ Visits 200Per day call rate in Local 13

Core Products O/S (Outstations)

DRS. Class No. of DRS. Visits/Month Total VisitsA-2(Outstations)

20 2 40

General Product O/S (Outstation)

DRS. Class No. of DRS. Visits/Month Total Visits

21

Mass Pharma (Private) LimitedA-2(Outstations)

20 2 40

Total NO of O/S Visits 80Per day call rate in O/S 10

13. Gift Plan:

Premier Gift (To be distributed by Manager)

Suit Pieces Mont blank pens Classy Pen holders Perfumes Imported Ties Leather Folder Gold Coins Branded Watches Wall Carpets

13.1 Event Gifts:

Azadi Gift in August

Family Gift for Doctors (Table Flag, Badges, Card)

Posters

Ramadan Offers

Digital Quran for selected customers

Dates

Tasbih

Jae Namaz

Eid Presents

Eid Cakes

22

Mass Pharma (Private) Limited Eid Cards

Eid Family Gifts (Mehndi, Churian, Morning Sweets)

New Year Gifts

Diaries

Calendars

New Year Night in some local or foreign hotel

Family Movie Shows

13.2 General Gifts

Wet Tissues

Tissue Containers

Big Clock

Wall Mounting (Miracles of ALLAH)

Beautiful Wooden Engraved Quran Verses for Table

Wooden Card holder

Wooden Pen holder

Wooden Key Chain

Ball Pens

Soaps

Towels

Juices and Apples Activities

23


14. Implementation of Control System:

We planned a very comprehensive reporting system for last year the implementation of same

reporting system will be ensured in this year with few amendments

14.1 Office Timings

Every member of field force will reach distribution office at 9:00 AM sharp and will

leave office eat 9:45 AM.

These 45 minutes are very valuable for Daffodil Team and every Manager and SPO

must have a plan or agenda to effectively utilize these 45 minutes.

This plan or agenda may include following things.

a) Delivery of Orders to Distributorb) Meeting with Sales man of your area and get feedback of your territoryc) Meeting of SPO with manager to exchange and to achieve the objectives on each sided) A small 10 minutes briefing on products of the day by managerse) Revise the essential features and benefits of the productsf) 5-10 minutes review of the doctors of the day and prescription vs ROI statusg) Check h) Check the sales statement and manage the daily need of targets

14.2 Reporting System for Managers

Weekly Report:

This report must be emailed to the marketing @ masspharma.com on every Monday. Format for

this report are available online in email IDS (copy attached in the end of this document). No

excuse in this regard will be acceptable.

24

Mass Pharma (Private) LimitedTour Plan:

Monthly tour plan of all managers and SPO’s must be emailed to the above given email ID latest

by 20th of every month. Managers are responsible for on time sending of these plans.

Weekly Work Plan:

Formats have already been dispatched to all managers. It is pocket size plan. Every manager will

keep this plan in his front pocket during daily working. Every senior from HO will focus this

plan for combined working. No excuse will b accepted in this regard, Sales Managers will be

directly responsible if any of his RSM/DFM’s will not follow the instructions.

Manager will fill the following formats with their weekly work plan.

DCR’s of entire teams Advanced weekly work plan (copy of pocket size plan)

14.3 Expense Statement Submission:

All Daffodil Managers must ensure the submission of expenses by their all field force by 15th of

every month

SPO Feedback Format:

This format is available in your respective email boxes

It must be filled by the managers fortnightly and must be emailed to marketing office on

regular basis.

Pre-active Report:

For the recommendation of any project, it is mandatory to fill the pre-activity report format

which is available in your respective inboxes. Without this report, no activity will be approved.

14.4 MGM Report

Two formats will be used for this purpose

Pre-MGM Report:

This report must reach marketing office at least one week before the day of activity. The

approved of MGM will be granted on the bases of this report. No MGM activity will be

approved without this report.

Post-MGM Report:

25

Mass Pharma (Private) LimitedThis report will be sent to the marketing office on next day of activity through e-mail, it will be

complete report covering

Complete detail of MGM Participants of MGM Focus Specialties Business against the activities

Any manager who does not submit the post activity report his upcoming MGM activity will be

withheld.

26


15. E-mail IDS (Daffodil Group)

Region E-mail PasswordKhyber Region [email protected] 123456Malakand Region [email protected] 123456Potohar Region [email protected] 123456Allam Iqbal Region [email protected] 123456Chenab Region [email protected] 123456Shalimar Region [email protected] 123456Buz Region [email protected] 123456Moen Jo Daro Region [email protected]

m123456

Mehran Region [email protected] 123456

27

mailto:[email protected]











16. Incentive Policy

SPO’s PS’s

Achievement Level Incentives85% to 99% 4% of the sales of core & General100% to above 5% of the sales of core & General90% & above of special products targets achievement of managers

2% of the sales of special products if these products are sold in his territory

DFM’s RSM’s & ASM’s

Achievement level at distirct & Regional Targets

Incentives

85% to 99% 1% to the sales of core & General Products100 & above 1.5% of sales of core & General Products90% & above of his special Products targets achievement

3% of sales of special Products

How to Quality this Incentive

1. This incentive scheme will be on quarterly targets achievement basis

2. Brick wise Distributor sales statements will be a pre-requisite for this scheme

3. Distributors clearances of payment and assurance of non return of stocks is essential

4. DFM’s/RSM’s qualify for his special products incentive if their SPO’s achieve their

targets of core & general products as per above mentioned criteria 85% to 99% or above

100% & their special products targets will be achieved 90% & above

28

Mass Pharma (Private) Limited5. SPO’s and PS’s whose targets are achieved & their manager’s special products target is

also achieved then they will be given 2% of those special products sales in their area

6. OTD sales will be separately rewarded and will not be included in market sales and

above mentioned incentive criteria.

7. Institutional business will be directly supplied through factory and will not be included in

market sales. However manager and concerned SPO will be separately rewarded.

17. Criteria of Incentives

No Managers SPO’s/PS’s Status of Incentive for SPO’s/PS’s

Status of Incentive for

managers1 Special Products

AchievedCore & General Products Achieved

Yes Yes

2 Special Product Not Achieved

Core & General Products Achieved

Yes No

3 Special Products Achieved

Core & General Products NOT Achieved

No No

29


Counlusion

Heart is the most importatn element in the human being. And over life depand on it. To day most

of the people are victiom of the heart patinet. They need a regular treatment for the heart and

after some time the trestment they need a anti tablet for stop the effect of heart tablet. Over tablet

GLIP is one of the product from the use of it you no need a anti tablet for a long time and its

negative effet is min.

Over product like the most of the people and doctor due the its goodnes.

30


Questioner for Heart Patient

Name: ______________

Gender: ______________

1. People become heart patient due to Depression?

a) Yes b) No

2. People become heart patient due to family history?

a) Yes b) No

3. Are you heart patient

a) Yes b) No

4. How much person alive from first heart attack?

a) 50% b) 65% c) 80%

5. Do you need a medicine after heart attack?

a) Yes b) No

6. Which company tablet you use?

a) Mass Pharma b) CCL Pharma c) Himont Pharma

7. Which one table you use

a) Getryl b) Evopride c) Orinase

8. Do you need anti table after using the heart tablet?

a) Yes b) No

9. After how much time you need anti tablet?31

Mass Pharma (Private) Limiteda ) 4 month b) 6 month c) 8 month

10. Which one anti table you use

a) Pharmayl b) Blaze

32

Final Project

Documents

mass pharma marketing

board of mass pharma

mass pharma private

introductionmass pharma

pharma industry of pakistan

manufacturing process

manufacturing facilities

marketing sales